Drug repositioning is the process of applying known drugs or compounds that are in development in new disease areas.

Intomics track record:

We have worked with clients on repositioning of drugs in different disease areas. Upon conclusion of some of these projects the clients have informed us, that they intended to start clinical trials for the drug in a new indication.

The value to our customers:

In general, the cost of launching a known drug for a new indication, is lower than a full drug development process. The effects of a known drug will already be characterized to a large degree and the drug will already have passed a significant number of test parameters, incl. toxicity, ADME etc.

What we do:

Our Drug Repositioning service provides unique features in identifying novel indications for your existing drug. Through big data analysis combining molecular data, literature information and phenotypic data, a mechanistic pathway is constructed for your drug. This is further related to potential diseases and symptoms, hereby mapping out the possible indication space for your drug. The text mining includes our proprietary inBio Know™ data mining platform and for protein-protein interaction networks we apply our proprietary PPI network database, inBio Map™.

Project Planning:

We work closely with our clients in the planning of each project. Each project is tailored specifically to generate the most valuable outcome, taking available data, in-house capabilities, timelines etc. into account.


The duration of drug repositioning projects is usually from 4 to 12 months, depending on the complexity of the project.

Close project cooperation and communication:

A key factor in the successful outcomes with our partners, is the close interaction and communication we have from planning the projects and all the way through project execution and presentation of the project deliverables. We typically have bi-weekly Webex update/planning meetings with the client and have face-to-face meetings every 2-3 months during the project. At the end of the project, we present the project deliverables and conclusions in a face-to-face meeting. All face-to-face meetings take place at our clients’ facility, unless another location is desired.


The deliverable is a comprehensive report including a thorough mapping of the possible indication space for your drug. Apart from the biomarker/signature list, the report also documents the project steps and details key project findings. Additionally, we present potential next steps in the project for discussion, if relevant.

What we do

Drug target identification

Helping clients identify genes/proteins as target candidates with remarkable results.

Biomarker discovery

Helping clients uncover clinical relevant biomarkers in complex diseases enabling precise patient stratification.

Drug repositioning

Helping clients in investigating the potential of repositioning marketed drugs into other disease areas.

Translational services

Helping clients decide on the correct model test platform for optimal drug development results.

Multi-marker development

Helping clients identify the patients most likely to benefit from a treatment with specific drugs.

Client Infrastructure

Helping clients build and evolve their inhouse bioinformatic capabilities with expert counseling.